Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy
Radiotherapy (RT) is one of the most common treatments for cancer. However, intracellular glutathione (GSH) plays a key role in protecting cancer from radiation damage. Herein, we have developed a platelet membrane biomimetic nanomedicine (PMD) that induces double GSH consumption to enhance tumor ra...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Pharmaceutical Analysis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177924000030 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582198099705856 |
|---|---|
| author | Xiaopeng Li Yang Zhong Pengyuan Qi Daoming Zhu Chenglong Sun Nan Wei Yang Zhang Zhanggui Wang |
| author_facet | Xiaopeng Li Yang Zhong Pengyuan Qi Daoming Zhu Chenglong Sun Nan Wei Yang Zhang Zhanggui Wang |
| author_sort | Xiaopeng Li |
| collection | DOAJ |
| description | Radiotherapy (RT) is one of the most common treatments for cancer. However, intracellular glutathione (GSH) plays a key role in protecting cancer from radiation damage. Herein, we have developed a platelet membrane biomimetic nanomedicine (PMD) that induces double GSH consumption to enhance tumor radioimmunotherapy. This biomimetic nanomedicine consists of an external platelet membrane and internal organic mesoporous silica nanoparticles (MON) loaded with 2-deoxy-D-glucose (2-DG). Thanks to the tumor-targeting ability of the platelet membranes, PMD can target and aggregate to the tumor site, which is internalized by tumor cells. Within tumor cells overexpressing GSH, MON reacts with GSH to degrade and release 2-DG. This step initially depletes the intracellular GSH content. The subsequent release of 2-DG inhibits glycolysis and adenosine triphosphate (ATP) production, ultimately leading to secondary GSH consumption. This nanodrug combines dual GSH depletion, starvation therapy, and RT to promote immunogenic cell death and stimulate the systemic immune response. In the bilateral tumor model in vivo, distal tumor growth was also well suppressed. The proportion of mature dendritic cells (DC) and CD8+ T cells in the mice was increased. This indicates that PMD can promote anti-tumor radioimmunotherapy and has good prospects for clinical application. |
| format | Article |
| id | doaj-art-d208846f6e2a44a38761fc980c5054a0 |
| institution | Kabale University |
| issn | 2095-1779 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Pharmaceutical Analysis |
| spelling | doaj-art-d208846f6e2a44a38761fc980c5054a02025-01-30T05:13:57ZengElsevierJournal of Pharmaceutical Analysis2095-17792024-12-011412100935Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapyXiaopeng Li0Yang Zhong1Pengyuan Qi2Daoming Zhu3Chenglong Sun4Nan Wei5Yang Zhang6Zhanggui Wang7Department of Radiation Oncology, Anhui No. 2 Provincial People's Hospital, Hefei, 230031, ChinaDepartment of Radiation Oncology, Anhui No. 2 Provincial People's Hospital, Hefei, 230031, ChinaDepartment of Electronic Science and Technology, School of Physics and Technology, Wuhan University, Wuhan, 430072, ChinaDepartment of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, ChinaDepartment of Radiation Oncology, Anhui No. 2 Provincial People's Hospital, Hefei, 230031, ChinaDepartment of Radiation Oncology, Anhui No. 2 Provincial People's Hospital, Hefei, 230031, ChinaDepartment of Radiation Oncology, Anhui No. 2 Provincial People's Hospital, Hefei, 230031, ChinaDepartment of Radiation Oncology, Anhui No. 2 Provincial People's Hospital, Hefei, 230031, China; Corresponding author.Radiotherapy (RT) is one of the most common treatments for cancer. However, intracellular glutathione (GSH) plays a key role in protecting cancer from radiation damage. Herein, we have developed a platelet membrane biomimetic nanomedicine (PMD) that induces double GSH consumption to enhance tumor radioimmunotherapy. This biomimetic nanomedicine consists of an external platelet membrane and internal organic mesoporous silica nanoparticles (MON) loaded with 2-deoxy-D-glucose (2-DG). Thanks to the tumor-targeting ability of the platelet membranes, PMD can target and aggregate to the tumor site, which is internalized by tumor cells. Within tumor cells overexpressing GSH, MON reacts with GSH to degrade and release 2-DG. This step initially depletes the intracellular GSH content. The subsequent release of 2-DG inhibits glycolysis and adenosine triphosphate (ATP) production, ultimately leading to secondary GSH consumption. This nanodrug combines dual GSH depletion, starvation therapy, and RT to promote immunogenic cell death and stimulate the systemic immune response. In the bilateral tumor model in vivo, distal tumor growth was also well suppressed. The proportion of mature dendritic cells (DC) and CD8+ T cells in the mice was increased. This indicates that PMD can promote anti-tumor radioimmunotherapy and has good prospects for clinical application.http://www.sciencedirect.com/science/article/pii/S2095177924000030Dual GSH consumptionCancer radioimmunotherapyPlatelet membrane biomimetic nanomedicineStarvation therapyOrganic mesoporous silica nanoparticles |
| spellingShingle | Xiaopeng Li Yang Zhong Pengyuan Qi Daoming Zhu Chenglong Sun Nan Wei Yang Zhang Zhanggui Wang Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy Journal of Pharmaceutical Analysis Dual GSH consumption Cancer radioimmunotherapy Platelet membrane biomimetic nanomedicine Starvation therapy Organic mesoporous silica nanoparticles |
| title | Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy |
| title_full | Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy |
| title_fullStr | Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy |
| title_full_unstemmed | Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy |
| title_short | Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy |
| title_sort | platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy |
| topic | Dual GSH consumption Cancer radioimmunotherapy Platelet membrane biomimetic nanomedicine Starvation therapy Organic mesoporous silica nanoparticles |
| url | http://www.sciencedirect.com/science/article/pii/S2095177924000030 |
| work_keys_str_mv | AT xiaopengli plateletmembranebiomimeticnanomedicineinducesdualglutathioneconsumptionforenhancingcancerradioimmunotherapy AT yangzhong plateletmembranebiomimeticnanomedicineinducesdualglutathioneconsumptionforenhancingcancerradioimmunotherapy AT pengyuanqi plateletmembranebiomimeticnanomedicineinducesdualglutathioneconsumptionforenhancingcancerradioimmunotherapy AT daomingzhu plateletmembranebiomimeticnanomedicineinducesdualglutathioneconsumptionforenhancingcancerradioimmunotherapy AT chenglongsun plateletmembranebiomimeticnanomedicineinducesdualglutathioneconsumptionforenhancingcancerradioimmunotherapy AT nanwei plateletmembranebiomimeticnanomedicineinducesdualglutathioneconsumptionforenhancingcancerradioimmunotherapy AT yangzhang plateletmembranebiomimeticnanomedicineinducesdualglutathioneconsumptionforenhancingcancerradioimmunotherapy AT zhangguiwang plateletmembranebiomimeticnanomedicineinducesdualglutathioneconsumptionforenhancingcancerradioimmunotherapy |